Open Journal Systems

Shifting paradigms in the management of metastatic and unresectable melanoma

Virender Suhag ()
Pankaj Vats ()


Cutaneous melanoma is regarded as the most aggressive form amongst all skin cancers. Although representing only 4% of all cancers, of the 132,000 people diagnosed globally each year, 37,000 will die. In 2017, approximately 87,110 new cases of melanoma will be diagnosed in the United States, of which approximately 9,730 patients will succumb to the disease.


melanoma; metastatic; unresectable; immunotherapy; novel agent

Full Text:



American Cancer Society. Cancer facts and figures. 2017 [Internet]. American Cancer Society Inc. [cited 2017 January 10]. Available from: editorial/documents/document/acspc-048738.pdf.

Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: Melanoma of the skin [Internet]. National Cancer Institute SEER Program [cited 2017 June 9]. Available from:

Erdmann F, Lortet-Tieulent J, Schüz J, Zeeb H, Greinert R, et al. International trends in the incidence of malignant melanoma 1953–2008 — Are recent generations at higher or lower risk? Int J Cancer 2013; 132(2): 385–400. doi: 10.1002/ijc.27616.

Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016. Eur J Cancer 2016; 63: 201–217. doi: 10.1016/j.ejca.2016.05.005.

Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013; 10(10): 588–598. doi: 10.1038/nrclinonc.2013.153.

Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016; 39(1): 98–106. doi: 10.1097/COC.0000000000000239.

Banzi M, Blasio SD, Lallas A, Longo C, Moscarella E, et al. Dabrafenib: A new opportunity for the treatment of BRAF V600-positive melanoma. Onco Targets Ther 2016; 9: 2725–2733. doi: 10.2147/OTT.S75104.

Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev 2013; 2013(6): CD008955. doi: 10.1002/14651858.cd008955.pub2.

Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D. Immunotherapy in melanoma: Recent advances and future directions. Eur J Surg Oncol 2017; 43(3): 604–611. doi: 10.1016/j.ejso.2016.07.145

Pennock GK, Chow LQM. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist 2015; 20(7): 812–822. doi: 10.1634/theoncologist.2014-0422.

Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 2015; 37(4): 764–782. doi: 10.1016/j.clinthera.2015.02.018.

Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2016; 14(4): 450–473. doi: 10.6004/jnccn.2016.0051.

Simeone E, Grimaldi AM, Festino L, Vanella V, Palla M, et al. Combination treatment of patients with BRAF-mutant melanoma: A new Standard of care. BioDrugs 2017; 31(1): 51–61. doi: 10.1007/s40259-016-0208-z.

Solus JF, Kraft S. Ras, Raf, and MAP kinase in melanoma. Adv Anat Pathol 2013; 20(4): 217–226. doi: 10.1097/PAP.0b013e3182976c94.

Wellbrock C, Arozarena I. The complexity of the ERK/MAP-Kinase pathway and the treatment of melanoma skin cancer. Front Cell Dev Biol 2016; 4: 33. doi: 10.3389/fcell.2016.00033.

Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: Latest evidence and place in therapy. Ther Adv Med Oncol 2016; 8(1): 48–56. doi: 10.1177/1758834015616934.

Redman JM, Gibney GT, Atkins MB. Advances in immunotherapy for melanoma. BMC Med 2016; 14: 20. doi: 10.1186/s12916-016-0571-0.

Kee D, McArthur G. Immunotherapy of melanoma. Eur J Surg Oncol 2017; 43(3): 594–603. doi: 10.1016/j.ejso.2016.07.014.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, et al. Future perspectives in melanoma research: Meeting report from the “Melanoma Bridge”. Napoli, December 1st–4th 2015. J Transl Med 2016; 14(1): 313. doi: 10.1186/s12967-016-1070-y.

Johnson AS, Crandall H, Dahlman K, Kelley MC. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma. J Am Coll Surg 2015; 220(4): 581–593.e1. doi: 10.1016/j.jamcollsurg.2014.12.057.



  • There are currently no refbacks.

Copyright (c) 2018 Virender Suhag, Pankaj Vats

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.